Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Akriti Seth
As a part of its strategy to develop its own ANDAs for essential medications, Civica has expressed interest in taking over existing ANDAs that are being retired or withdrawn by other generics manufacturers.
NBK Capital Partners has acquired a majority stake in Polymedic, which is based in Morocco, the sixth largest pharmaceutical market in Africa that is expected to reach $2bn in 2020.
Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.
Mundipharma and Samsung Bioepis are undertaking an exclusive commercialization partnership for a portfolio of biosimilars in Hong Kong and Taiwan.
Novo Nordisk says it is offering solutions to the unaffordability and inaccessibility of insulin by launching US authorized generics of its NovoLog and NovoLog Mix brands. The originator is also introducing a ‘My$99Insulin’ plan and an ‘immediate supply’ option to “help people with diabetes who need alternative solutions.”
Pointing out the “critical shortcomings of the Blocking Act” in a new report, the AAM has urged the US Congress to re-evaluate the legislation.